Related Experiment Videos
[Clinical study on cefprozil fine granules]
The Japanese Journal of Antibiotics
|December 1, 1992
Summary
Cefprozil (CFPZ) demonstrated 100% clinical efficacy in pediatric infectious diseases. This new cephem antibiotic showed excellent safety, with only one case of eosinophilia reported in 15 patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Background:
- Cefprozil (CFPZ) is a novel non-ester cephem antibiotic.
- Pediatric infectious diseases require effective and safe treatment options.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Cefprozil (CFPZ) in pediatric patients.
- To assess the therapeutic outcomes and adverse effects of CFPZ in children.
Main Methods:
- Oral administration of Cefprozil (CFPZ) at 18.5-41.7 mg/kg/day for 3-8 days.
- Study included 15 pediatric patients (6 boys, 9 girls) aged 10 months to 11 years.
- Clinical efficacy and side effects were monitored throughout the treatment period.
Main Results:
- Cefprozil (CFPZ) achieved an overall clinical efficacy rate of 100%.
- Excellent efficacy was observed in 3 patients, and good efficacy in 12 patients.
- One patient experienced eosinophilia; no other adverse effects were reported.
Conclusions:
- Cefprozil (CFPZ) is a highly effective antibiotic for treating infectious diseases in pediatric populations.
- The safety profile of Cefprozil (CFPZ) in children is favorable, with minimal side effects observed.